AAM
RYTM icon

Advisors Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Advisors Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.43M Buy
21,896
+3,178
+17% +$287K 0.04% 556
2026
Q1 		$1.63M Buy
18,718
+194
+1% +$18.9K 0.03% 663
2025
Q4 		$1.98M Buy
18,524
+4,346
+31% +$461K 0.03% 596
2025
Q3 		$1.43M Buy
14,178
+582
+4% +$54K 0.02% 694
2025
Q2 		$859K Buy
13,596
+3,346
+33% +$205K 0.02% 810
2025
Q1 		$543K Buy
10,250
+3,176
+45% +$176K 0.01% 916
2024
Q4 		$396K Buy
+7,074
New +$391K 0.01% 976

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Advisors Asset Management's RYTM Position: Q2 2026 in Review

Advisors Asset Management increased its Rhythm Pharmaceuticals (RYTM) stake by 17% in Q2 2026, buying an estimated $287K and bringing the position to 21,896 shares worth $2.43M. The position accounts for 0.04% of the portfolio, ranked #556.

Advisors Asset Management first reported a position in RYTM in Q4 2024 and has held it in 7 quarters since. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Advisors Asset Management held 21,896 shares of Rhythm Pharmaceuticals worth $2.43M as of Q2 2026.
  • Advisors Asset Management bought 3,178 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $287K.
  • Rhythm Pharmaceuticals made up 0.04% of Advisors Asset Management's portfolio in Q2 2026, its #556 holding.
  • Advisors Asset Management first reported a position in Rhythm Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.